Advertisement

Updates in the Metabolic Management of Calcium Stones

  • Kristina L. Penniston
  • Stephen Y. Nakada
Endourology (P Mucksavage, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Endourology

Abstract

Purpose of Review

Urinary risk factors, such as hypercalciuria, hypocitraturia, and hyperoxaluria, either in combination or alone, are associated with calcium stones. Dietary habits as well as underlying medical conditions can influence urinary risk factors. Evaluation of the conglomerate of patients’ stone risks provides evidence for individualized medical management, an effective and patient-supported approach to prevention.

Recent Findings

Many patients with stones desire prevention to avoid repeated surgical interventions. Yet, recent practice pattern assessments and health care utilization data show that many patients are rarely referred for metabolic evaluation or management. Innovations in metabolic management over the past decade have improved its effectiveness in reducing risk and preventing calcium stones. Although no new pharmacologic agents for calcium stone prevention have recently become available, there is relatively new thinking about some diet-based approaches.

Summary

This review will synthesize current evidence to support individualized metabolic management of calcium stones.

Keywords

Metabolic management Medical management Prevention Diet Urolithiasis Nephrolithiasis 

Notes

Compliance with Ethical Standards

Conflict of Interest

Kristina L. Penniston reports personal fees from Retrophin.

Stephen Y. Nakada declares no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    • Kittanamongkolchai W, Vaughan LE, Enders FT, Dhondup T, Mehta RA, Krambeck AE, et al. The changing incidence and presentation of urinary stones over 3 decades. Mayo Clin Proc. 2018;  https://doi.org/10.1016/j.mayocp.2017.11.018. In addition to evaluating trends in kidney stone incidence from 1984 to 2012 within a well-described cohort of patients in Olmsted County, Minnesota, the authors also provide a summary of studies in other regions in the U.S. Findings concur that stone incidence is rising among women and adolescents.
  2. 2.
    López M, Hoppe B. History, epidemiology and regional diversities of urolithiasis. Pediatr Nephrol. 2010;25:49–59.  https://doi.org/10.1007/s00467-008-0960-5.CrossRefPubMedGoogle Scholar
  3. 3.
    •• Kum F, Mahmalji W, Hale J, Thomas K, Bultitude M, Glass J. Do stones still kill? An analysis of death from stone disease 1999–2013 in England and Wales. BJU Int. 2016;118:140–4.  https://doi.org/10.1111/bju.13409. While it may be tempting to assume that kidney stones are now a largely benign condition, the authors provide evidence from England and Wales that stones are still a cause of death into the 21st century. CrossRefPubMedGoogle Scholar
  4. 4.
    Lange JN, Wood KD, Wong H, Otto R, Mufarrij PW, Knight J, et al. Sensitivity of human strains of Oxalobacter formigenes to commonly prescribed antibiotics. Urology. 2012;79:1286–9.  https://doi.org/10.1016/j.urology.2011.11.017.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Kharlamb V, Schelker J, Francois F, Jiang J, Holmes RP, Goldfarb DS. Oral antibiotic treatment of helicobacter pylori leads to persistently reduced intestinal colonization rates with Oxalobacter formigenes. J Endourol. 2011;25:1781–5.  https://doi.org/10.1089/end.2011.0243.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    •• Gambaro G, Croppi E, Coe F, Lingeman J, Moe O, Worcester E, et al. Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. J Nephrol. 2016;29:715–34. A statement from 44 European and U.S. experts in metabolic management of calcium stones who met in 2015. Statements on 27 key questions, identified by a steering committee, were developed to “inform clinicians on…secondary forms of calcium nephrolithiasis” and their clinical management. The premise of the statement was that recent guidelines of the American Urological Association and the European Association of Urology did not address relevant topics in the field of idiopathic calcium nephrolithiasis. CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    •• Skolarikos A, Straub M, Knoll T, Sarica K, Seitz C, Petřík A, et al. Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. Eur Urol. 2015;67:750–63.  https://doi.org/10.1016/j.eururo.2014.10.029. In this statement, the authors describe the “optimum metabolic evaluation strategy” for patients with single and recurrent urinary stones. Findings are presented in the form of diagnostic protocols and specific therapeutic algorithms. CrossRefPubMedGoogle Scholar
  8. 8.
    • Prezioso D, Strazzullo P, Lotti T, Bianchi G, Borghi L, Caione P, et al. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group. Arch Ital Urol Androl. 2015;87:105–20.  https://doi.org/10.4081/aiua.2015.2.105. Comprehensive review and analysis of publications related to the management of urinary risk factors for urolithiasis using diet. Specific dietary strategies are recommended for each urinary risk factor. CrossRefPubMedGoogle Scholar
  9. 9.
    Pearle MS, Goldfarb DS, Assimos DG, Curhan G, Denu-Ciocca CJ, Matlaga BR, et al. Medical management of kidney stones: AUA guidelines. J Urol. 2014;192:316–24.  https://doi.org/10.1016/juro2014.05.006.CrossRefPubMedGoogle Scholar
  10. 10.
    • Tang R, Jiang Y, Tan A, Ye J, Xian X, Xie Y, et al. 16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones. Urolithiasis. 2018;  https://doi.org/10.1007/s00240-018-1037-y. One of three studies available in PubMed to compare global gut microbial profiles (i.e., not simply of oxalotrophs) of urolithiasis patients with controls. The study was small (13 patients). Further studies are needed to corroborate results.
  11. 11.
    • Stern JM, Moazami S, Qiu Y, Kurland I, Chen Z, Agalliu I, et al. Evidence for a distinct gut microbiome in kidney stone formers compared to non-stone formers. Urolithiasis. 2016;44:399–407.  https://doi.org/10.1007/s00240-016-0882-9. One of three studies available in PubMed to compare global gut microbial profiles (i.e., not simply of oxalotrophs) of urolithiasis patients with controls. The study was small (23 patients) and included patients with different stone types and stone histories. Further studies are needed to corroborate results. CrossRefPubMedGoogle Scholar
  12. 12.
    • Suryavanshi MV, Bhute SS, Jadhav SD, Bhatia MS, Gune RP, Shouche YS. Hyperoxaluria leads to dysbiosis and drives selective enrichment of oxalate metabolizing bacterial species in recurrent kidney stone endures. Sci Rep. 2016;6:34712.  https://doi.org/10.1038/srep34712. One of three studies available in PubMed to compare global gut microbial profiles (i.e., not simply of oxalotrophs) of urolithiasis patients with controls. This study was larger (24 patients), it included only recurrent patients with confirmed stones at the time of sampling, and 24-hour urine oxalate was evaluated and compared to gut microbe results. However, only male participants were included. Interestingly, while Oxalobacter formigenes, an obligate oxalate user, did not differ between patients and controls, the presence of oxalate metabolizing enzymes was higher in patients than controls. CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Vaidyanathan S, von Unruh GE, Watson ID, Laube N, Willets S, Soni BL. Hyperoxaluria, hypocitraturia, hypomagnesiuria, and lack of intestinal colonization by Oxalobacter formigenes in a cervical spinal cord injury patient with suprapubic cystostomy, short bowel, and nephrolithiasis. Sci World J. 2006;6:2403–10.CrossRefGoogle Scholar
  14. 14.
    Mittal RD, Kumar R, Mittal B, Prasad R, Bhandari M. Stone composition, metabolic profile and the presence of the gut-inhabiting bacterium Oxalobacter formigenes as risk factors for renal stone formation. Med Princ Pract. 2003;12:208–13.CrossRefPubMedGoogle Scholar
  15. 15.
    Rugendorff EW. Urology and philately: a philatelic ramble through urology. New York NY: 2005.Google Scholar
  16. 16.
    Poulakou-Rebelakou E, Rempelakos A, Tsiamis C, Dimopoulos C. “I will not cut, even for the stone”: origins of urology in the Hippocratic collection. Int Braz J Urol. 2015;41:26–9.  https://doi.org/10.1590/S1677-5538.IBJU.2015.01.05. CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Chakravorty RC. Urinary stones their cause and treatment as described in the sushrutasamhita. Hist Sci Med. 1982;17:328–32.PubMedGoogle Scholar
  18. 18.
    Changizi Ashtiyani S, Cyrus A. Rhazes, a genius physician in diagnosis and treatment of kidney calculi in medical history. Iran J Kidney Dis. 2010;4:106–10.PubMedGoogle Scholar
  19. 19.
    Fisang C, Anding R, Müller SC, Latz S, s LN. Urolithiasi—an interdisciplinary diagnostic, therapeutic and secondary preventive challenge. Dtsch Arztebl Int. 2015;112:83–91.  https://doi.org/10.3238/arztebl.2015.0083. PubMedPubMedCentralGoogle Scholar
  20. 20.
    Romero V, Akpinar H, Assimos DG. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol. 2010;12:e86–96.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Richet G. Nephrolithiasis at the turn of the 18th to 19th centuries: biochemical disturbances. A genuine cascade giving rise to clinical chemistry. Am J Nephrol. 2002;22:254–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Stow LR, Gumz ML. The circadian clock in the kidney. J Am Soc Nephrol. 2011;22:598–604.  https://doi.org/10.1681/ASN.2010080803.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Flock RH. Prophylaxis and medical management of calcium urolithiasis: the role of the quantity and precipitability of the urinary calcium. J Urol. 1940;44:183–90.CrossRefGoogle Scholar
  24. 24.
    Knapp EL. Factors influencing the urinary excretion of calcium in normal persons. J Clin Invest. 1947;26:182–202.CrossRefPubMedCentralGoogle Scholar
  25. 25.
    Hodgkinson A. The urinary excretion of oxalic acid in nephrolithiasis. Proc R Soc Med. 1958;51:970–1.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Kleeman CR, Bohannan J, Bernstein D, Ling S, Maxwell MH. Effect of variations in sodium intake on calcium excretion in normal humans. Proc Soc Exp Biol Med. 1964;115:29–32.CrossRefPubMedGoogle Scholar
  27. 27.
    Jr LJ, Piering WF, Lennon EJ. Possible role of carbohydrate-induced calciuria in calcium oxalate kidney-stone formation. N Engl J Med. 1969;280:232–7.  https://doi.org/10.1056/NEJM196901302800502.CrossRefGoogle Scholar
  28. 28.
    Lamberg BA, Kuhlback B. Effect of chlorothiazide and hydrochlorothiazide on the excretion of calcium in urine. Scand J Clin Lab Invest. 1959;11:351–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Abdulhadi MH, Hall PM, Streem SB. Hypocitraturia and its role in renal stone disease. Cleve Clin J Med. 1988;55:242–5.CrossRefPubMedGoogle Scholar
  30. 30.
    Kuo RL, Aslan P, Abrahamse PH, Matchar DB, Preminger GM. Incorporation of patient preferences in the treatment of upper urinary tract calculi: a decision analytical view. J Urol. 1999;162:1913–9.  https://doi.org/10.1016/S0022-5347(05)68067-6.CrossRefPubMedGoogle Scholar
  31. 31.
    Penniston KL, Nakada SY. Health related quality of life differs between male and female stone formers. J Urol. 2007;178:2435–40.CrossRefPubMedGoogle Scholar
  32. 32.
    Sterrett SP, Moore NW, Nakada SY. Emergency room follow-up trends in urolithiasis: single-center report. Urology. 2009;73:1195–7.  https://doi.org/10.1016/j.urology.2008.07.057.CrossRefPubMedGoogle Scholar
  33. 33.
    •• Dauw CA, Alruwaily AF, Bierlein MH, Asplin JR, Ghani KR, Wolf JS Jr, et al. Provider variation in the quality of metabolic stone management. J Urol. 2015;193:885–90.  https://doi.org/10.1016/j.juro.2014.09.111. The authors reviewed nearly 210,000 patients who underwent initial metabolic evaluation and found that only 16% had follow-up evaluation. Patients who saw a urologist had significantly lower odds of repeat testing vs. those who saw a primary provider. CrossRefPubMedGoogle Scholar
  34. 34.
    Canales BK, Richards NG, Peck AB. Rapid oxalate determination in blood and synthetic urine using a newly developed oxometer. J Endourol. 2013;27:145–8.  https://doi.org/10.1089/end.2012.0438.CrossRefPubMedGoogle Scholar
  35. 35.
    Goldfarb DS, Arowojolu O. Metabolic evaluation of first-time and recurrent stone formers. Urol Clin N Am. 2013;40:13–20.  https://doi.org/10.1016/j.uci.2012.09.007.CrossRefGoogle Scholar
  36. 36.
    Healy KA, Hubosky SG, Bagley DH. 24-hour urine collection in the metabolic evaluation of stone formers: is one study adequate? J Endourol. 2013;27:374–8.  https://doi.org/10.1089/end.2012.0216.CrossRefPubMedGoogle Scholar
  37. 37.
    Castle SM, Cooperberg MR, Sadetsky N, Eisner BH, Stoller ML. Adequacy of a single 24-hour urine collection for metabolic evaluation of recurrent nephrolithiasis. J Urol. 2010;184:579–83.  https://doi.org/10.1016/j.juro.2010.03.129.CrossRefPubMedGoogle Scholar
  38. 38.
    Penniston KL. Dietary assessment of patients who form kidney stones. In: Lowry P, Penniston KL, editors. Nutrition therapy for urolithiasis. Springer: Springer International Publishing AG; 2018.Google Scholar
  39. 39.
    Liebman M, Al-Wahsh IA. Probiotics and other key determinants of dietary oxalate absorption. Adv Nutr. 2011;2:254–60.  https://doi.org/10.3945/an.111.000414.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Klimesova K, Whittamore JM, Hatch M. Bifidobacterium animalis subsp. lactis decreases urinary oxalate excretion in a mouse model of primary hyperoxaluria. Urolithiasis. 2015;43:107–17.  https://doi.org/10.1007/s00240-014-0728-2.CrossRefPubMedGoogle Scholar
  41. 41.
    Siener R, Bade DJ, Hesse A, Hoppe B. Dietary hyperoxaluria is not reduced by treatment with lactic acid bacteria. J Transl Med. 2013;11:306.  https://doi.org/10.1186/1479-5876-11-306.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Hatch M, Freel RW. A human strain of Oxalobacter (HC-1) promotes enteric oxalate secretion in the small intestine of mice and reduces urinary oxalate excretion. Urolithiasis. 2013;41:379–84.  https://doi.org/10.1007/s00240-013-0601-8.CrossRefPubMedGoogle Scholar
  43. 43.
    Lieske JC, Tremaine WJ, De Simone C, O’Connor HM, Li X, Bergstralh EJ, et al. Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation. Kidney Int. 2010;78:1178–85.  https://doi.org/10.1038/ki.2010.310.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Penniston KL, Nakada SY. Treatment expectations and health-related quality of life in stone formers. Curr Opin Urol. 2016;26:50–5.  https://doi.org/10.1097/MOU.0000000000000236.CrossRefPubMedGoogle Scholar
  45. 45.
    Kalantari K, Bolton WK. A good reason to measure 24-hour urine creatinine excretion, but not to assess kidney function. Clin J Am Soc Nephrol. 2013;8:1847–9.  https://doi.org/10.2215/CJN.09770913.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Heymsfield SB, Arteaga C, McManus C, Smith J, Moffitt S. Measurement of muscle mass in humans: validity of the 24-hour urinary creatinine method. Am J Clin Nutr. 1983;37:478–94.CrossRefPubMedGoogle Scholar
  47. 47.
    • Curhan GC. Nephrolithiasis. In: Kasper D, Fauci A, Hauser S, Longo D, Jameson JL, Loscalzo, editors. Harrison’s principles of internal medicine, 19e: McGraw-Hill Education: McGraw-Hill Companies, Inc.; 2015. The author makes a compelling argument in favor of interpreting 24-hour urinary stone risk parameters as continuous variables and provides an approach for individualized medical stone prevention. Google Scholar
  48. 48.
    Johnson RK. Dietary intake—how do we measure what people are really eating. Obes Res. 2002;10:63S–8S.CrossRefPubMedGoogle Scholar
  49. 49.
    He FJ, Marciniak M, Carney C, Markandu ND, Anand V, Fraser WD, et al. Effects of potassium chloride and potassium bicarbonate on endothelial function, cardiovascular risk factors, and bone turnover in mild hypertensives. Hypertension. 2010;55:681–8.CrossRefPubMedGoogle Scholar
  50. 50.
    Kohn JB. Is medical nutrition therapy appropriate for kidney stones. J Acad Nutr Diet. 2014;114:1496.  https://doi.org/10.1016/j.jand.2014.07.015.CrossRefPubMedGoogle Scholar
  51. 51.
    Wallace TC. Twenty years of the dietary supplement health and education act—how should dietary supplements be regulated? J Nutr. 2015;145:1683–6.  https://doi.org/10.3945/jn.115.211102.CrossRefPubMedGoogle Scholar
  52. 52.
    Noori N, Honarkar E, Goldfarb DS, Kalantar-Zadeh K, Taheri M, Shakhssalim N, et al. Urinary lithogenic risk profile in recurrent stone formers with hyperoxaluria: a randomized controlled trial comparing DASH (Dietary Approaches to Stop Hypertension)-style and low-oxalate diets. Am J Kidney Dis. 2014;63:456–63.  https://doi.org/10.1053/j.ajkd.2013.11.022.CrossRefPubMedGoogle Scholar
  53. 53.
    Miller AW, Dale C, Dearing MD. Microbiota diversification and crash induced by dietary oxalate in the mammalian herbivore Neotoma albigula. mSphere. 2017;2  https://doi.org/10.1128/mSphere.00428-17.
  54. 54.
    Ohashi Y, Andou A, Kanaya M, Harada K, Fujisawa T. Acetogenic bacteria mainly contribute to the disposal of hydrogen in the colon of healthy Japanese. Bioscience Microflora. 2009;28:17–9.CrossRefGoogle Scholar
  55. 55.
    Holma R, Osterlund P, Sairanen U, Blom M, Rautio M, Korpela R. Colonic methanogenesis in vivo and in vitro and fecal pH after resection of colorectal cancer and in healthy intact colon. Int J Color Dis. 2012;27:171–8.  https://doi.org/10.1007/s00384-011-1323-4.CrossRefGoogle Scholar
  56. 56.
    Singh SB, Lin HC. Hydrogen sulfide in physiology and diseases of the digestive tract. Microorganisms. 2015;3:866–89.  https://doi.org/10.3390/microorganisms3040866.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Ticinesi A, Nouvenne A, Borghi L, Meschi T. Water and other fluids in nephrolithiasis: state of the art and future challenges. Crit Rev Food Sci Nutr. 2017;57:963–74.  https://doi.org/10.1080/10408398.2014.964355.CrossRefPubMedGoogle Scholar
  58. 58.
    Siener R. Can the manipulation of urinary pH by beverages assist with the prevention of stone recurrence? Urolithiasis. 2016;44:51–6.  https://doi.org/10.1007/s00240-015-0844-7.CrossRefPubMedGoogle Scholar
  59. 59.
    Sumorok NT, Asplin JR, Eisner BH, Stoller ML, Goldfarb DS. Effect of diet orange soda on urinary lithogenicity. Urol Res. 2012;40:237–41.  https://doi.org/10.1007/s00240-011-0418-2.CrossRefPubMedGoogle Scholar
  60. 60.
    Baia Lda C, Baxmann AC, Moreira SR, Holmes RP, Heilberg IP. Noncitrus alkaline fruit: a dietary alternative for the treatment of hypocitraturic stone formers. J Endourol. 2012;26:1221–6.  https://doi.org/10.1089/end.2012.0092.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Clinical Nutrition ServicesUniversity of Wisconsin Hospital and ClinicsMadisonUSA
  2. 2.Department of UrologyUniversity of Wisconsin School of Medicine and Public HealthMadisonUSA
  3. 3.Department of MedicineUniversity of Wisconsin School of Medicine and Public HealthMadisonUSA
  4. 4.Department of RadiologyUniversity of Wisconsin School of Medicine and Public HealthMadisonUSA

Personalised recommendations